Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 1,717 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,717 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.66, for a total transaction of $562,592.22. Following the transaction, the executive vice president directly owned 25,181 shares in the company, valued at approximately $8,250,806.46. This trade represents a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, March 3rd, Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50.
• On Friday, February 13th, Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36.
• On Monday, January 12th, Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $8.65 on Wednesday, reaching $327.30. The stock had a trading volume of 931,139 shares, compared to its average volume of 1,481,848. The firm has a market capitalization of $43.41 billion, a PE ratio of 191.40 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The firm has a 50-day moving average of $357.29 and a 200 day moving average of $417.03. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the firm posted ($0.65) earnings per share. The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $27,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Finally, Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of analyst reports. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Wells Fargo & Company lowered their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Barclays started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target for the company. Leerink Partners decreased their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Finally, Royal Bank Of Canada dropped their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.